BIOGEN INC. (BIIB) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 30 days, typically, give or take 5 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Oct 28, 2026before open 28 8-K
Q2 FY2026Wed, Jul 29, 2026before open 29 8-K
Q1 FY2026Wed, Apr 29, 2026before open 29 8-K
Q4 FY2025Fri, Feb 6, 2026before open 37 8-K
Q3 FY2025Thu, Oct 30, 2025before open 30 8-K
Q2 FY2025Thu, Jul 31, 2025before open 31 8-K
Q1 FY2025Thu, May 1, 2025before open 31 8-K
Q4 FY2024Wed, Feb 12, 2025before open 43 8-K

What they guided beta

Q3 FY2026 "Full year 2026 Non-GAAP diluted EPS guidance: Biogen raises the lower end of the reported range to $12.20 to $13.00 from $12.00 to $13.00 reflecting ongoing business strength and Apellis dilution favorability Biogen Inc. (Nasdaq: BIIB) today reported third quarter 2026 financial results." exhibit
Q3 FY2026 "“With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders." Third Quarter 2026 Growth Portfolio In-Market Revenue Summary ($ in millions) Q3 '26 Q3 '25 △ Commentary SPINRAZA $461 $374 23% Accelerated conversion to high-dose regimen continues to exceed Company expectations across all launched markets LEQEMBI 3 $202 $121 67% Continued sequential growth; U.S. in-market sales of $107M VUMERITY $192 $215 (11)% Impacted primarily by U.S. formulary dynamics SYFOVRE 4" exhibit
Q3 FY2026 "The Company expects to announce top line data from both TOPAZ-1 and TOPAZ-2 Phase 3 studies, evaluating litifilimab in SLE, in the first half of December 2026." exhibit
Q3 FY2026 "Additional Phase 3 readouts expected for litifilimab in CLE, felzartamab in antibody mediated rejection in the first half of 2027 and zorevunersen in Dravet syndrome in the third quarter of 2027. 3 Full Year 2026 Financial Guidance Biogen is raising the lower end of the reported full year 2026 Non-GAAP diluted EPS guidance range to reflect ongoing business strength and Apellis dilution favorability." exhibit
Q3 FY2026 "Full year 2026 Non-GAAP diluted EPS range is expected as follows: FY 2026 Non-GAAP Diluted EPS Guidance February 2026 July 2026 October 2026 Underlying guidance $15.25 to $16.25 $15.85 to $16.85 $15.95 to $16.75 Expected approximate impact from acquired IPR&D, upfront and milestone charges -- ~($3.00) ~($3.20) Expected dilution from the Apellis acquisition ~($0.85) ~($0.55) Reported Guidance $15.25 to $16.25 $12.00 to $13.00 $12.20 to $13.00 Full year total revenue is expected to increase by a mid-single digit percentage for 2026 as compared to 2025 driven by continued growth from our Growth P" exhibit
Q2 FY2026 "EMPAVELI revenue of $46 million for the full second quarter, up 123% year-over-year, driven by demand growth. $30 million of revenue recognized by Biogen following the close of the Apellis acquisition on May 14, 2026 1 Growth Portfolio includes EMPAVELI, QALSODY, SKYCLARYS, SPINRAZA, SYFOVRE, VUMERITY, ZURZUVAE, plus Biogen's 50% share of net revenue and cost of sales, including royalties, from the LEQEMBI Collaboration AMR = antibody mediated rejection; CLE = cutaneous lupus erythematosus; SLE = systemic lupus erythematosus 1 The Company is now advancing the next potential wave of growth driv" exhibit
Q2 FY2026 "Registrational data for litifilimab in SLE expected by end of 2026 and additional Phase 3 readouts for litifilimab in CLE, felzartamab in AMR, and zorevunersen in Dravet syndrome anticipated next year" exhibit
Q2 FY2026 "Pending RayThera acquisition expected to add multiple immunology programs to Biogen’s portfolio, including a lead program now in Phase 1 development Apellis acquisition now completed with strong second quarter 2026 revenue performance for SYFOVRE and EMPAVELI." exhibit
Q2 FY2026 "With the integration progressing well, Biogen expects approximately $0.85 dilution to Non-GAAP diluted EPS for full year 2026, driven largely by lower interest income and higher interest expense associated with the transaction financing, and remains on track for the transaction to be accretive to Non-GAAP diluted EPS in 2027." exhibit
Q2 FY2026 "Transaction run rate synergies exiting 2027 are expected to be at least $250 million." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/BIIB
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/BIIB

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

BIIB earnings date badge

HTML

<a href="https://veritasdata.dev/company/BIIB/"><img src="https://veritasdata.dev/embed/BIIB.svg" alt="BIIB earnings date" width="240" height="56"></a>

Markdown

[![BIIB earnings date](https://veritasdata.dev/embed/BIIB.svg)](https://veritasdata.dev/company/BIIB/)

Script

<script async src="https://veritasdata.dev/embed/BIIB.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/BIIB"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.